Hangzhou Zenshine Pharmaceuticals Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Hangzhou China (2018)

Organization Overview

First Clinical Trial
2020
NCT04504708
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Nanjing Zenshine Pharmaceuticals | Zenshine Pharmaceutical, Inc. | Zenshine Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

zx-7101a (8 trials)

Drugs in Phase 2 Trials (1)

zx-101a (3 trials)

Drugs in Phase 1 Trials (2)

oseltamivir (tamiflu) (1 trial)

zx-4081 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hematologic Neoplasms (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 4